HRASLS3 (PLA2G16) (NM_001128203) Human Recombinant Protein
CAT#: TP325152
Recombinant protein of human phospholipase A2, group XVI (PLA2G16), transcript variant 2
Specifications
Product Data | |
Species | Human |
Expression Host | HEK293T |
Expression cDNA Clone or AA Sequence |
Recombinant protein was produced with TrueORF clone, RC225152. Click on the TrueORF clone link to view cDNA and protein sequences.
|
Tag | C-Myc/DDK |
Predicted MW | 17.8 kDa |
Concentration | >50 ug/mL as determined by microplate BCA method |
Purity | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Buffer | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol |
Preparation | Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. |
Storage | Store at -80°C. |
Stability | Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
Reference Data | |
RefSeq | NP_001121675 |
Locus ID | 11145 |
UniProt ID | P53816, A0A024R561 |
Cytogenetics | 11q12.3-q13.1 |
Refseq Size | 1111 |
Refseq ORF | 486 |
Synonyms | AdPLA; H-REV107; H-REV107-1; HRASLS3; HREV107; HREV107-1; HREV107-3; HRSL3; PLA2G16; PLAAT-3 |
Summary | Lipid-modifying enzyme that acts as major regulator of adipocyte lipolysis by catalyzing the release of fatty acids from phospholipids in adipose tissue (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). Shows phospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in various phosphatidylcholines (PC) and phosphatidylethanolamine (PE) (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). For most substrates, phospholipase A1 activity is much higher than phospholipase A2 activity (PubMed:19047760). Phospholipase activity causes decreased intracellular levels of ether-type lipids, affecting peroxisome metabolism (By similarity). May also have acyltransferase activity: catalyzes both N-acylation of phosphatidylethanolamine to form N-acyl-phosphatidylethanolamine and O-acylation of lyso-phosphatidylcholines to form phosphatidylcholines (PubMed:22605381, PubMed:25383759). The relevance of acyltransferase activity in vivo is however unclear and would require additional evidences (PubMed:22605381, PubMed:25383759). Also has weak lysophospholipase activity. [UniProtKB/Swiss-Prot Function] |
Protein Families | Druggable Genome, Transmembrane |
Documents
FAQs |
SDS |
Resources
Recombinant Protein Resources |
Other Versions
SKU | Description | Size | Price |
---|---|---|---|
LC416202 | PLA2G16 HEK293T cell transient overexpression lysate (as WB positive control) |
USD 121.00 |
|
LC426918 | PLA2G16 HEK293T cell transient overexpression lysate (as WB positive control) |
USD 121.00 |
|
LY416202 | Transient overexpression lysate of phospholipase A2, group XVI (PLA2G16), transcript variant 1 |
USD 396.00 |
|
LY426918 | Transient overexpression lysate of phospholipase A2, group XVI (PLA2G16), transcript variant 2 |
USD 396.00 |
|
PH300242 | PLA2G16 MS Standard C13 and N15-labeled recombinant protein (NP_009000) |
USD 2,055.00 |
|
PH325152 | PLA2G16 MS Standard C13 and N15-labeled recombinant protein (NP_001121675) |
USD 2,055.00 |
|
TP300242 | Recombinant protein of human phospholipase A2, group XVI (PLA2G16), transcript variant 1 |
USD 823.00 |
{0} Product Review(s)
Be the first one to submit a review